Bio-Techne Stock Surges 37% as Institutional Investors Reshape Holdings
Bio-Techne Corp shares have surged approximately 37% over the past month as institutional investors adjust their holdings in the Minnesota-based life sciences company. The company surpassed quarterly revenue expectations with $295.88 million, while recently divesting Exosome Diagnostics to focus on higher-margin core segments.